Short Interest in iSpecimen Inc. (NASDAQ:ISPC) Rises By 119.2%

iSpecimen Inc. (NASDAQ:ISPC) saw a significant increase in short interest in the month of May. As of May 15th, there was short interest totaling 112,840 shares, an increase of 119.2% from the April 30th total of 51,489 shares. Based on an average daily volume of 1,080,390 shares, the short-interest ratio is presently 0.1 days. Currently, 8.9% of the shares of the company are sold short.

iSpecimen Trading Down 4.8%

Shares of NASDAQ ISPC traded down $0.16 during midday trading on Friday, hitting $3.16. The company’s stock had a trading volume of 140,836 shares, compared to its average volume of 795,140. The stock has a fifty day moving average price of $5.10 and a 200 day moving average price of $11.31. The firm has a market capitalization of $4.54 million, a price-to-earnings ratio of -0.04 and a beta of 1.75. iSpecimen has a one year low of $3.11 and a one year high of $127.20.

iSpecimen (NASDAQ:ISPC) last posted its earnings results on Friday, May 15th. The company reported ($6.66) earnings per share for the quarter. The firm had revenue of $0.16 million for the quarter. iSpecimen had a negative return on equity of 584.65% and a negative net margin of 1,080.16%.

Institutional Trading of iSpecimen

A hedge fund recently bought a new stake in iSpecimen stock. Scientech Research LLC bought a new position in shares of iSpecimen Inc. (NASDAQ:ISPC) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned 0.30% of iSpecimen at the end of the most recent quarter. 13.62% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on ISPC shares. Weiss Ratings reissued a “sell (e+)” rating on shares of iSpecimen in a research report on Tuesday, April 21st. Wall Street Zen raised shares of iSpecimen to a “sell” rating in a research report on Saturday, May 2nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

About iSpecimen

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.